Clinical Trials | June 01, 2026
Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial
This marks one of the most closely watched oncology readouts at this year’s medical congress
This marks one of the most closely watched oncology readouts at this year’s medical congress
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
The company is building a connected healthcare ecosystem that utilises smart healthcare kiosk and mobile app to deliver at-home, AI-assisted health screenings and non-invasive health measurements
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
